期刊文献+

激素冲击疗法联合免疫抑制剂治疗狼疮危象的临床疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨激素冲击疗法联合免疫抑制剂在狼疮危象中的治疗效果。方法将我院2014年8月至2015年8月期间收治的50例狼疮危象患者为研究对象,采用随机数字表法分为两组,即研究组与对照组。研究组25例狼疮患者给予激素加环磷酰胺进行治疗,对照组25例狼疮患者则接受激素加霉酚酸酯进行治疗,对两组患者临床疗效进行对比。结果经对比得出,研究组患者治疗的有效率为90.00%,对照组患者则为63.33%,研究组患者疗效高于对照组,且对比差异显著,有统计学意义(P<0.05)。结论应用激素加环磷酰胺治疗狼疮危象患者临床疗效较好,易被患者所接,值得临床有效推广以及应用。
出处 《中国医药指南》 2016年第23期62-62,共1页 Guide of China Medicine
  • 相关文献

参考文献4

二级参考文献32

  • 1李汉桐 伍锦泉 等.联合冲击治疗狼疮肾炎伴脑病[J].中华肾脏病杂志,1999,15:206-206.
  • 2栗占国,胡大一.风湿免疫内科[M].北京:北京科学技术出版社,2010:138.
  • 3Hanly JG, Mecurdy G, Fougere L,et al. Neuropspchiatric events in systemic lupus erythematosus attribution and clinical significance[ J]. Rhcumatol,2004,31 ( 11 ) :2156 - 2162.
  • 4Doria A, Iaccarino L, Chiradello A, et al. Long - term prognosis and cause of death in systemic lupus erythmatosus[ J]. Am J Meal,2006, 119:700 - 706.
  • 5Badsha H,Kong KO,Lian TY, et al. Low - dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications[J]. Lupus,2002,11 (8) :508 -513.
  • 6Mackworth-Young CG, David J, Morgan SH, et al. A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus [ J]. Ann Rheum Dis, 1988,47 (6) :496-502.
  • 7Kanno A, Hotta O, Yusa N, et al. Redictive factors of clinical out- come in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy [ J ]. Ren Fail, 2007,29 ( 1 ) :41-47.
  • 8Merrill JT, NeuwelCM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythema- tosus : the randomized, double-blind, phase Ⅱ / Ⅲ systemic lupus erythematosus evaluation of rituximab trial [ J ]. Arthritis Rheum, 2010,62( 1 ) :222-233.
  • 9Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of ritux- imab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study [ J ]. Arthritis Rheum, 2012,64(4) : 1215-1226.
  • 10Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safe- ty of belimumab in patients with active systemic lupus erythemato- sus: a randomized, placebo-controlled, phase 3 trial[J]. Lancet, 2011,377 (9767) :721-731.

共引文献8

同被引文献19

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部